HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Factors associated with non-adherence to HBV antiviral therapy.

AbstractBACKGROUND:
HBV antiviral therapy has the potential to reduce the burden of HBV-related liver disease by suppressing HBV DNA replication to undetectable levels, reducing the progression of liver fibrosis and reducing the risk of hepatocellular carcinoma (HCC) development. Treatment outcomes and long-term benefits require adherence to medication regimens. This study aimed to identify the prevalence and factors associated with non-adherence to antiviral therapy.
METHODS:
A cross-sectional survey of patients receiving HBV antiviral therapies was conducted in three Sydney hospitals. Participants were asked to complete an online questionnaire. Logistic regression was used to assess the associations between non-adherence (defined as missing more than 1 day of medication in the last 30 days) and demographic, socio-economic, disease, treatment, health-care system and individual-related factors.
RESULTS:
Of the 277 participants, 66 (23.8%) were non-adherent, missing a mean 1.7 days of medication (sd 4.8) in the last 30 days. In multivariate analysis, non-adherent behaviour declined with age (odds ratio [OR] 0.9, 95% CI 0.97, 0.99; P<0.013). Participants who reported having no established routine to take their medication (OR 5.0, 95% CI 1.4, 17.4; P<0.012) and having inadequate health literacy (OR 2.7, 95% CI 1.3, 5.5; P<0.007) were more likely to be non-adherent.
CONCLUSIONS:
Almost a quarter of participants in the current study were non-adherent. Adherence is potentially modifiable through person-centred education, collaborative models of patient care and interventions designed to improve health literacy and establish medication routines. Findings have the potential to improve health service delivery to patients at risk of non-adherence to HBV antiviral therapy.
AuthorsSuzanne Sheppard-Law, Iryna Zablotska-Manos, Melissa Kermeen, Susan Holdaway, Alice Lee, Jacob George, Amany Zekry, Lisa Maher
JournalAntiviral therapy (Antivir Ther) Vol. 23 Issue 5 Pg. 425-433 ( 2018) ISSN: 2040-2058 [Electronic] England
PMID29355830 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiviral Agents
  • DNA, Viral
Topics
  • Adult
  • Aged
  • Antiviral Agents (therapeutic use)
  • Cross-Sectional Studies
  • DNA, Viral (genetics, metabolism)
  • Female
  • Follow-Up Studies
  • Health Knowledge, Attitudes, Practice
  • Hepatitis B virus (drug effects, genetics, metabolism, pathogenicity)
  • Hepatitis B, Chronic (drug therapy, pathology, psychology, virology)
  • Humans
  • Logistic Models
  • Male
  • Medication Adherence (psychology, statistics & numerical data)
  • Middle Aged
  • Multivariate Analysis
  • Odds Ratio
  • Risk Factors
  • Surveys and Questionnaires
  • Virus Replication (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: